Pharma: Other News To Note
Tuesday, March 12, 2013
Moberg Derma AB, of Stockholm, Sweden, said it is discontinuing the development of Limtop, a formulation of imiquimod, in actinic keratosis.
Outside of the US
Part of Thomson Reuters
Note: our contact information has changed
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
© 2017 Thomson Reuters. Reproduction, reposting content is strictly prohibited.